Related references
Note: Only part of the references are listed.Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study
Zhibin Chen et al.
JAMA NEUROLOGY (2018)
Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy
Michele A. Faulkner
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Efficacy of perampanel in a patient with epilepsia partialis continua
H. Argente-Escrig et al.
EPILEPSY & BEHAVIOR CASE REPORTS (2017)
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial
Jacqueline A. French et al.
NEUROLOGY (2015)
Adverse effects and safety profile of perampanel: A review of pooled data
Fergus Rugg-Gunn
EPILEPSIA (2014)
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307
Gregory L. Krauss et al.
EPILEPSIA (2014)
Development of perampanel in epilepsy
A. Satlin et al.
ACTA NEUROLOGICA SCANDINAVICA (2013)
Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305
Jacqueline A. French et al.
EPILEPSIA (2013)
Perampanel, a selective, noncompetitive aleph-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307
Gregory L. Krauss et al.
EPILEPSIA (2013)
Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies
Bernhard J. Steinhoff et al.
EPILEPSIA (2013)
Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures
Ivan Rektor
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Tolerability and safety of perampanel: two randomized dose-escalation studies
G. L. Krauss et al.
ACTA NEUROLOGICA SCANDINAVICA (2012)
Diagnosis and management of the epilepsies in children: a summary of the partial update of the 2012 NICE epilepsy guideline
Richard E. Appleton et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2012)
A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus
Laura Ceolin et al.
NEUROCHEMISTRY INTERNATIONAL (2012)
Adjunctive perampanel for refractory partial-onset seizures Randomized phase III study 304
Jacqueline A. French et al.
NEUROLOGY (2012)
Randomized phase III study 306 Adjunctive perampanel for refractory partial-onset seizures
G. L. Krauss et al.
NEUROLOGY (2012)
Patterns of treatment response in newly diagnosed epilepsy
M. J. Brodie et al.
NEUROLOGY (2012)
Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy
Takahisa Hanada et al.
EPILEPSIA (2011)
Antiepileptic Drug Interactions - Principles and Clinical Implications
Svein I. Johannessen et al.
Current Neuropharmacology (2010)
Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Erik K. St. Louis
CURRENT NEUROPHARMACOLOGY (2009)
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs
PN Patsalos et al.
LANCET NEUROLOGY (2003)
Epilepsy after the first drug fails: substitution or add-on?
P Kwan et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2000)
Share Paper
